Upfront Bevacizumab/témozolomide for Gliomastomas With Neurological Impairment | MicrobiomeTrials← Back to trialsNCT03623347
Upfront Bevacizumab/témozolomide for Gliomastomas With Neurological Impairment
CompletedOBSERVATIONAL
Trial Details
Start: 2011-01-01Est. Completion: 2017-05-12
Enrollment target: 70 participants Locations- CHU Amiens-Picardie, Amiens, France
Other microbiome trials you might be interested in
Small Cell Lung Carcinoma
Lung cancer is a highly prevalent disease worldwide in women and men. In 2022, lung cancer stood as the most frequently …
A Coruña, SpainEst. completion Jun 30, 2029
Nasopharyngeal CarcinomaNasopharyngeal CancerNasopharynx CarcinomaNasopharynx Cancer
The purpose of this study is to find out whether cemiplimab, with or without fianlimab, is an effective treatment for ad…
Basking Ridge, United StatesEst. completion Jul 2030
Cervical Cancer
This is a prospective, multi-center, randomized controlled phase II clinical trial aimed at exploring the efficacy evalu…
Shanghai, ChinaEst. completion Dec 31, 2028